Tempus AI's IPO Next Week: What Investors Need to Know

On June 14, 2024, Tempus AI, a health tech company specializing in precision medicine through artificial intelligence, will be launching its IPO. As this date approaches, here's a comprehensive look at what Tempus AI offers, its financial health, market position, leadership, and the potential risks for investors.

Company Overview

Tempus AI was founded in 2015 by Eric Lefkofsky, driven by a mission to revolutionize healthcare through AI-enhanced diagnostics. The company focuses on Intelligent Diagnostics, using artificial intelligence to improve the accuracy and personalization of laboratory tests. This is enabled by the Tempus Platform, which integrates vast amounts of clinical and molecular data to deliver more precise diagnostic insights.

‍

Tempus AI claims to have one of the largest collections of clinical and molecular oncology data globally, supporting its suite of diagnostic products that have seen significant adoption over the past five years.

Financial Performance

Tempus AI plans to raise around $410 million through its IPO by offering 11.1 million shares priced between $35 and $37 each, aiming for a valuation of up to $6.1 billion. The company will list on the Nasdaq under the ticker symbol "TEM" (Reuters).

‍

In 2023, Tempus AI generated $531.8 million in revenue, up from $320.7 million in 2022. For the first quarter of 2024, the company recorded $145.8 million in revenue, compared to $115.6 million for the same period the previous year.

‍

Despite this revenue growth, Tempus AI has not yet achieved profitability. In 2023, it reported a net loss of $214.1 million, down from a $289.8 million loss in 2022. For the first quarter of 2024, the net loss was $64.7 million, up from $54.4 million a year earlier.

Market Position and Partnerships

Tempus AI’s unique approach combines AI technology with clinical care, setting it apart from traditional diagnostic laboratories. This strategy has attracted major pharmaceutical clients such as AstraZeneca and GSK.

‍

The company has also secured significant funding from prominent investors, including SoftBank, Google, and Franklin Templeton, raising a total of $1.42 billion (Reuters).

‍

Leadership

Eric Lefkofsky, Tempus AI’s founder and CEO, is a seasoned entrepreneur with experience in taking companies public. He previously co-founded Groupon and has led other ventures to successful IPOs. However, his career has not been without controversy, particularly regarding his handling of Groupon's financials and personal gains from pre-IPO rounds (TechCrunch).

‍

At Tempus AI, Lefkofsky has foregone a salary for the past two years, although he is slated to receive substantial compensation starting in 2025. His shares in Tempus carry 30 votes per share, giving him considerable control over the company’s future.

Risks and Considerations

Investing in Tempus AI involves several risks. The company is still unprofitable and continues to incur significant losses. The IPO prospectus indicates that Tempus AI will need to raise additional capital in the future, which could dilute existing shares and affect the stock price negatively.

‍

Moreover, while Tempus AI markets itself as an AI company, AI-related revenues accounted for only a small fraction of its total revenue in 2023. The company’s success hinges on its ability to integrate AI more effectively into its diagnostic tools and demonstrate its value.

‍

Lefkofsky’s extensive control over the company, combined with past controversies, may also be a concern for some investors. His significant voting power could impact corporate decisions in ways that might not always align with the best interests of all shareholders.

‍For further information, you can visit Tempus AI’s official website.